Psoriatic arthritis places a high burden on patient quality of life (QoL), productivity (indirect costs), and healthcare resources (direct costs).26, 27 A literature review of 49 studies evaluating the burden of PsA revealed 2 studies that showed that the average annual direct and indirect cost associated with PsA ranged from ≈$8,367 to $18,110.*,9 Hospitalizations accounted for almost 60% of direct costs, whereas disability and lost productivity accounted for the majority of indirect costs.9 Both direct and indirect costs increased with worsening physical functioning and increased disease activity.9 Indirect costs accounted for 52% to 72% of the total costs.9
Studies report that nearly one-third of patients with PsA claimed short-term or permanent disability, and that employment rates ranged from 54% to 63%.9 A number of factors were associated with work disability, including disease duration and severity, education, gender, and type of employment.9
Unfortunately for those living with PsA, there is no validated assessment tool to diagnose PsA and there are no universally accepted guidelines used to guide treatment.
†Defined as time away from work and reduced effectiveness at work
Husted et al performed a single-center, Canadian, cross-sectional study to determine the pattern of comorbidities among patients with PsA.29 The study included 631 patients with PsA.29 The most prevalent comorbid condition in PsA patients was “other musculoskeletal conditions,” followed by hypertension.29 The study found that 42.2% of patients with PsA had 3 or more comorbidities.29
The high rate of comorbidities, which include cardiovascular risk factors, diabetes, obesity, chronic pulmonary disease, and autoimmune conditions, may complicate therapy selection and utilization.29
Learn about the unmet need in psoriatic arthritis.